EGFR and non-small cell lung carcinoma: Among previous RCTs evaluating the efficacy of adjuvant EGFR–TKIs, the EVAN phase II trial was the first to show a significantly higher OS benefit from erlotinib than from chemotherapy (vinorelbine plus cisplatin) in patients with resected stage IIIA EGFR-mutant NSCLC [29].